*A trial to assess administration Probenecid or Cyclosporine on PK of LEO 152020 in healthy people
Research type
Research Study
Full title
*A phase 1, open-label, fixed-sequence trial to investigate the effect of coadministration of probenecid or cyclosporine on the pharmacokinetics of LEO 152020 in healthy subjects
IRAS ID
1006240
Contact name
Trine Christiansen
Contact email
Sponsor organisation
LEO Pharma A/S
Clinicaltrials.gov Identifier
Research summary
Research Summary
The Study Drug is an investigational drug being developed by the sponsor as a potential treatment for eczema and for patients with recurring skin hives.
The current treatments for eczema and recurring hives have side effects or might not be very effective, and it is hoped that the Study Drug will be more effective with fewer side effects.
To date, the Study Drug has been tested extensively in animals at doses higher than the dose planned for this trial. It has also been tested in two trials in healthy human participants. The Study Drug has been well-tolerated so far with few side effects at the dose levels proposed for this trial.
This will be a drug-drug interaction study. The main purpose of this study is to determine whether potential interactions between the Study Drug and other drugs (probenecid and cyclosporine) exist. Drug drug interaction studies have an important role in drug development, and this study is being performed as part of the development program for the Study Drug.Summary of Results
Study enrolled no patients, so there are no available data or results.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
22/NW/0278
Date of REC Opinion
3 Nov 2022
REC opinion
Further Information Favourable Opinion